Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

• Status: Recruiting
• Trial end date: 2023-07-01

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. It is not yet known which regimen of combination chemotherapy given together with or without monoclonal antibodies is more effective in treating patients with newly diagnosed acute lymphoblastic leukemia.

PURPOSE: This randomized phase III trial is studying standard chemotherapy to see how well it works when given together with or without rituximab, and with or without nelarabine in treating patients with newly diagnosed acute lymphoblastic leukemia.

• Phase: Phase 3

Details

• Lead Sponsor: University College London Hospitals; University College, London
• Treatments: 6-Mercaptopurine; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Fludarabine; Fludarabine phosphate; Imatinib Mesylate; Melphalan; Mercaptopurine; Methotrexate; Pegaspargase; Rituximab; Vincristine